Context Therapeutics Inc.

Context Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapy product candidates for cancer. Its pipeline includes CTIM-76, CT-95 and CT-202, and the company is currently focused on advancing these assets through preclinical work and early-stage clinical trials while seeking regulatory approval and future commercialization.

8.52

8.52

— Context Therapeutics Inc.
%
Clinical-stage product candidates0% Includes CTIM-76, CT-95 and CT-202 being advanced through nonclinical and early clinical development.
Research and development services100% Internal discovery, preclinical testing, clinical trial execution and regulatory preparation for pipeline assets.
Licensing and asset acquisition0% In-licensed or acquired programs and related intellectual property, know-how and regulatory assets.

Context Therapeutics does not yet sell approved products; its current 'customers' are primarily clinical trial sites,...

  • Clinical development partnersprimary

    CROs, investigators and trial sites that execute preclinical studies and Phase 1 trials for CTIM-76, CT-95 and CT-202.

  • Manufacturing and supply chain partnersprimary

    Contract manufacturers and suppliers that provide drug substance, drug product and clinical trial materials.

  • Future oncology treatment providersemerging

    Hospitals, cancer centers and physicians that would prescribe approved therapies to patients with cancer.

  • Strategic licensing counterpartiessecondary

    Biotech licensors and collaborators that provide assets, IP or development rights to expand the pipeline.

The company is headquartered in the United States and its development and financing activities are centered there...

  • •Headquartered in the United States
  • •Clinical and corporate operations are U.S.-centric
  • •CT-95 IP is prosecuted in the U.S., Europe, Canada, Australia, Japan and Taiwan
  • •CT-202 is licensed worldwide from BioAtla
  • •No country revenue disclosure because the company has no product sales

Context Therapeutics is prioritizing advancement of its lead pipeline assets through early clinical development while...

01
Advance the lead pipeline through Phase 1 and first-in-human studiesshort-term

Clinical proof-of-concept is the main value driver for a pre-revenue biotech company.

02
Secure additional financing and extend cash runwayshort-term

The company has no product revenue and needs capital to fund R&D and operations.

03
Build manufacturing and regulatory capabilitiesmedium-term

Clinical supply and eventual commercialization require scalable external manufacturing and regulatory execution.

04
Expand and defend intellectual propertymedium-term

Patent protection is central to exclusivity, partnering leverage and eventual commercial value.

The company is highly exposed to clinical, financing and intellectual property risk because it has no approved products...

high

Financing risk

The company expects to need substantial additional capital and has no committed credit facility.

Scope
Operations into 2027 depend on assumptions that may prove inaccurate.
Materiality
high
high

Clinical development failure

Pipeline value depends on successful preclinical and Phase 1 results for CTIM-76, CT-95 and CT-202.

Scope
Any trial setback could delay or eliminate future commercialization.
Materiality
high
high

Intellectual property litigation

Third parties may assert patent claims or challenge the company’s rights to use key technology.

Scope
CTIM-76 and CT-95 are specifically exposed to third-party patent risk.
Materiality
high
medium

Regulatory delay risk

FDA and broader U.S. regulatory changes can slow approvals and increase compliance burden.

Scope
Early-stage oncology programs require multiple regulatory milestones.
Materiality
medium
medium

Supply chain and tariff risk

Imported raw materials and clinical supplies may become more expensive or harder to source.

Scope
Manufacturing scale-up and clinical supply continuity could be affected.
Materiality
medium
Research and development expense recognition
Quarterly results can fluctuate materially with trial activity and vendor accruals
Clinical trial accrual estimates
Accrual changes can move operating expenses and liabilities
License and asset acquisition accounting
Affects balance sheet assets, expense recognition and future impairment risk
Share-based compensation
Raises G&A and R&D expense without immediate cash outflow
Emerging growth company accounting
Financial statements may not be directly comparable to non-EGC biotech companies

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

BICYCLE THERAPEUTICS PLC

BCYC · Pharmaceutical Preparations

BioAtla, Inc.

BCAB · Biological Products, (No Diagnostic Substances)

: 28/04/2026